On this page
- Antiretroviral, nucleoside reverse transcriptase inhibitor
- HIV infection, in combination with other antiretrovirals
Forms and strengths
- 150 mg tablet
- 50 mg/5 ml oral solution
The daily dose is administered once daily or in 2 divided doses.
- Child 1 month and over and adult:
|Weight||Daily dose||50 mg/5 ml oral sol.||150 mg tablet|
|3 to < 6 kg||60 mg||3 ml x 2||–|
|6 to < 10 kg||80 mg||4 ml x 2||–|
|10 to < 14 kg||120 mg||6 ml x 2||–|
|14 to < 20 kg||150 mg||–||
½ tab x 2
or 1 tab x 1
|20 to < 25 kg||225 mg||–||
½ tab morning and 1 tab evening
or 1 ½ tab x 1
|≥ 25 kg||300 mg||–||
1 tab x 2
or 2 tab x 1
- Depending on the efficacy and tolerance of lamivudine.
Contra-indications, adverse effects, precautions
- Administer with caution to patients with history of hepatic disorders.
- May cause: gastrointestinal disturbances (diarrhoea, nausea, vomiting, etc.) and possibly: haematological disorders, especially when combined with zidovudine (neutropenia, anaemia, thrombocytopenia), myopathy, hepatic or pancreatic disorders.
- Reduce dosage in patients with renal impairment.
- Pregnancy: no contra-indication
- In neonates, the dosage of lamivudine 50 mg/5 ml (i.e. 10 mg/ml) solution is:
- 2 to < 3 kg: 0.5 ml 2 times daily (daily dose: 10 mg)
- 3 to < 4 kg: 0.8 ml 2 times daily (daily dose: 16 mg)
- 4 to < 5 kg: 1 ml 2 times daily (daily dose: 20 mg)
- Lamivudine is also used for HIV post-exposure prophylaxis, in combination with other antiretrovirals.
- Also comes in fixed-dose combinations with other antiretrovirals. Preferably use these formulations when available.
Below 25 °C
Once opened, oral solution keeps for 30 days maximum.